Araris Biotech is a biotechnology platform enables the attachment of any payload to ‘off the shelf’ antibodies.
Araris Biotech has raised €41M across 3 funding rounds from 9 investors, most recently a round in May 2023. Based in Zurich, Switzerland; founded 2019; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-05-05 | Other | €2.5M | Innosuisse | View deal → |
| 2022-10-04 | Other | €24M | 4BIO Capital,btov Partners,Institute for Follicular Lymphoma Innovation,Pureos Bioventures,Redalpine,Schroders Capital+2 more | View deal → |
| 2020-10-22 | Seed | €14M | Pureos Bioventures | View deal → |
